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Abstract
The identification of tumor antigens capable of eliciting an immune response in vivo may be an
effective method to identify therapeutic cancer targets. We have developed a method to identify such
antigens using frozen tumor-draining lymph node samples from breast cancer patients. Immune
responses in tumor-draining lymph nodes were identified by immunostaining lymph node sections
for B-cell markers (CD20&CD23) and Ki67 which revealed cell proliferation in germinal center
zones. Antigen-dependent somatic hypermutation (SH) and clonal expansion (CE) were present in
heavy chain variable (VH) domain cDNA clones obtained from these germinal centers, but not from
Ki67 negative germinal centers. Recombinant VH single-domain antibodies were used to screen
Correspondence to: Kevin P. Claffey.
NIH Public Access
Author Manuscript
Cancer Immunol Immunother. Author manuscript; available in PMC 2010 March 5.
Published in final edited form as:
Cancer Immunol Immunother. 2009 February ; 58(2): 221–234. doi:10.1007/s00262-008-0543-0.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
tumor proteins and affinity select potential tumor antigens. Neuroplastin (NPTN) was identified as
a candidate breast tumor antigen using proteomic identification of affinity selected tumor proteins
with a recombinant VH single chain antibody. NPTN was found to be highly expressed in
approximately 20% of invasive breast carcinomas and 50% of breast carcinomas with distal
metastasis using a breast cancer tissue array. Additionally, NPTN over-expression in a breast cancer
cell line resulted in a significant increase in tumor growth and angiogenesis in vivo which was related
to increased VEGF production in the transfected cells. These results validate NPTN as a tumor-
associated antigen which could promote breast tumor growth and metastasis if aberrantly expressed.
These studies also demonstrate that humoral immune responses in tumor-draining lymph nodes can
provide antibody reagents useful in identifying tumor antigens with applications for biomarker
screening, diagnostics and therapeutic interventions.
Keywords
Neuroplastin/SDR-1; Tumor antigen; Germinal center; Immune response; Breast cancer; Sentinel
lymph node
Introduction
The identification of novel tumor associated antigens (TAAs) can result in significant
improvements in the detection and treatment of malignant tumors. The ideal candidates are
antigens selectively expressed by tumor cells and those expressed in excess or in alternative
immunogenic forms in tumor cells compared to normal tissue. Proteins that bear these
characteristics are capable of eliciting an adaptive immune response and thus evaluating
immune responses in cancer patients is an excellent starting point for the discovery of new
TAAs.
Humoral immune responses to breast cancer have been extensively documented. Evidence for
their existence can be obtained at three levels: responses in tumor draining-lymph nodes, the
presence of antibodies in serum, and analysis of tumor infiltrating lymphocytes (TILs). In
tumor-draining lymph nodes, histological patterns suggestive of humoral responses, such as
germinal center hyperplasia, have been described for decades [19,42] and a relative abundance
of IgG+ B cells, indicative of a mature response, has also been observed [21,43]. Tumor reactive
serum antibodies are present in more than half of breast cancer patients analyzed and react with
several TAAs such as Her-2/Neu, MUC1 and p53 [7]. Finally, although T lymphocytes are the
predominant component of TILs in most breast cancers, significant B cell clusters can be
present in a small subset of cases [6,13]. Taken together, these observations indicate that the
humoral arm of the immune system can react to breast tumors. However, it has been hard to
prove that the immune responses are protective, as only a few are associated with a significantly
better prognosis and tumor regression is infrequent [7,14].
In spite of this, the study of humoral responses in individual patients may significantly improve
the discovery of TAAs which may serve as therapeutic targets. Tumor draining-lymph nodes,
the primary location for lymphocyte priming, represent a potential source of anti-tumor
antibodies. Accordingly, hybridomas generated with B cells extracted from axillary lymph
nodes have given rise to several antibodies that react with malignant tissue and/or breast cancer-
derived cell lines [2,9,12,21,22,30,35]. In these studies, cell suspensions from whole lymph
node sections were used and thus no selection criteria for tumor-responsive B cells were applied
prior to hybridoma fusion. Recent studies have provided evidence for clonal expansion (CE)
and somatic hypermutation (SH) in tumor infiltrating-B cells from breast cancer patients by
amplification and sequencing of rearranged immunoglobulin genes [8,27,38]. As these
parameters are reliable indicators of antigen-driven humoral responses, their identification in
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tumor draining-lymph node samples can reveal antibodies that have reacted to tumor antigens
in vivo and can provide an effective methodology to identify antigen-driven humoral responses
and a technology for tumor antigen identification.
Here, we generated Ig heavy chain variable domain (VH) gene cDNA libraries to evaluate the
presence of SH and CE in distinct lymph node zones defined by the presence of B cell activation
and cellular proliferation markers. This analysis guided the selection of VH sequences to be
used as recombinant single-domain antibodies (sdAbs) in an antigen-trap assay that led to the
discovery of a candidate TAA, neuroplastin (NPTN). Finally, we conducted experiments to
evaluate NPTN expression in breast cancer specimens and its effect on tumor biology that
validate it as a new TAA for breast cancer.
Materials and methods
Patient samples
Samples of primary breast tumors (>1.5 cm diameter) and medial sections of local draining
lymph nodes were obtained within 5–10 min of resection by a staff pathologist. The samples
were placed into optimal cutting temperature (OCT) media (Shandon Lipshaw, Pittsburgh, PA,
USA) and immediately frozen in liquid nitrogen. All samples were obtained under an
Institutional Review Board approved protocol and devoid of any personal identification
information.
Immunohistochemistry, tissue coring and RNA isolation
Lymph node cryosections (7–10 μm in thickness) were obtained and post-fixed with
methanol:acetone (1:1), dried and rehydrated in phosphate buffered saline (PBS). Immuno-
staining was performed on serial sections with anti-CD20 (Dako, Carpinteria, CA, USA), anti-
CD23 (BD Pharmingen, San Jose, CA, USA) or anti-Ki67 (Dako) and detected with Vector
ABC kit using DAB substrate according to the manufacturer's protocol (Vector Laboratories,
Burlingame, CA, USA). Controls without addition of primary antibody were performed to
assure signal specificity. Immuno-stained slides were imaged with a color digital camera (Zeiss
AxioCam HRc) and serial slide overlays were produced using Adobe Photoshop (Adobe
Systems, Inc., San Jose, CA, USA) and pixel-by-pixel color masks with Image-Pro Plus (Media
Cybernetics, Inc., Silver Spring, MD, USA) software. Selected areas of interest were identified
with a marker pen on the primary hematoxylin and eosin (H&E) stained slide and aligned with
the coordinate frozen tissue block. The area of interest was cored out of the block using a 1.0
mm copper core tube (Beecher Tissue Arrayer acceptor core, Beecher Instruments, Silver
Spring, MD, USA) sterilized with 0.5% SDS and 70% ethanol and the cored tissue was
transferred into RNA lysis buffer and total RNA isolated with the RNAeasy kit (Qiagen,
Valencia, CA, USA) according to the manufacturer's protocol.
cDNA synthesis, V gene amplification and generation of VH libraries
RNA yields from isolated cores were typically 2–6 μg. Two micrograms of RNA were
subjected to reverse transcription (RT) using Superscript II (Invitrogen, Carlsbad, CA, USA)
with random hexamer primers in a total reaction volume of 20 μl as described in the
manufacturer's protocol. One microliter of the RT reaction was amplified via PCR with
Platinum Pfx DNA Polymerase (Invitrogen) using a modification of degenerate primers
described previously [34]: forward primer 5′-ATGCAGGTGCAGCTGGTGSAGTCTG G-3′;
reverse primer: 5′-TGAGGAGACGGTGACCAKG GT-3′. Amplifications were initiated with
a 5 min hot start at 94°C followed by 30 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for
1 min each, and a terminal extension at 72°C for 10 min. PCR products were agarose gel
purified and terminal adenosine was added to purified fragments with Taq polymerase
(Invitrogen) and 200 μM ATP for 10 min at 72°C. Fragments were ligated into pCR-T7TOPO
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expression vector (Invitrogen) and resultant transformants were screened by PCR using Vent
DNA Polymerase (New England Biolabs, Beverly, MA, USA), forward primer: 5′-
CGCGAAATTAATACGACTCACTATAGGG-3′, and 3′ primer: 5′-
CCTAAATTGTAAGCGTTAATCCGG-3′. A positive screen resulted in a ∼730 bp PCR
fragment (∼410 bp VH sequence + ∼320 bp vector sequence). PCR fragments that screened
positive were separated from their primer precursors on a Qiagen MinElute 96 UF PCR
purification plate (Qiagen).
DNA sequencing and analysis
Purified VH PCR fragments were sequenced using a standard primer to the T7 promoter with
the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA),
and an ABI automated cycle sequencer (Applied Biosystems). To determine V, D and J gene
segment usage the sequences were aligned to sequences from the V BASE database using
DNAPLOT software at http://vbase.mrc-cpe.cam.ac.uk/. Each sequence was compared to
human germline sequence with the highest matching score to identify mutations in framework
regions (FRs) 1, 2 and 3 and complementarity-determining regions (CDRs) 1 and 2. To
establish if mutations in the CDRs were caused by antigen pressure, the multinomial
distribution model described by Lossos et al. [26] was applied using the applet provided at
http://www-stat.stanford.edu/immunoglobulin/.
Recombinant VH synthesis and purification
The sdAb proteins were synthesized in bacteria by amplifying clones of interest with in-frame
oligos for cloning into the pTrcHis2 C vector (Invitrogen) providing a fusion with C-terminal
c-myc and 6× His affinity purification tags. The fusion plasmid and induction of expression
by IPTG and purification from bacterial extracts was performed using histidine tag affinity
chromatography with Ni-NTA Columns (Clontech) according to the manufacturer's protocol.
Purified proteins were dialyzed overnight in 10 mM Tris–HCl, pH = 7.5, 150 mM NaCl, 0.5
mM EDTA at 4°C. VH fusion sdAB proteins were analyzed for protein recovery using the
BioRad DC reagent kit and immunoblot with anti-c-myc antibody (Invitrogen).
Breast tumor extracts and sdAB binding/LC-MS/MS identification
Primary breast tumor samples were obtained and immediately frozen. Frozen tissue was
directly homogenized in 5 volumes of lysis buffer (1% Triton X-100, 50 mM Hepes, pH 7.5,
10 mM sodium pyrophosphate, 150 mM NaCl, 100 mM NaF, 0.2 mM sodium orthovanadate,
1 mM EGTA, pH 7.5, 1.5 mM MgCl2, 10% glycerol, and fresh Protease Inhibitor Cocktail (10
μl/ml) (Sigma–Aldrich)), using a Polytron Homogenizer with 5 high-power burst to completely
homogenize the tissue. The tissue was centrifuged at 4°C once at 800×g and supernatant
centrifuged at 14,000×g to remove insoluble debris. Protein concentration was determined by
BioRad DC reagent using bovine serum albumin (BSA) as a standard. Purified sdAB
recombinant proteins (10 μg/ml) were allowed to bind to high capacity nickel assay plates
(Sigma–Aldrich) at 200 μl/well and washed 5× with phosphate binding buffer (PBS pH-7.5,
Tween-20 (0.01%), 5 mM imidazole) using an automated plate washer. Each antibody was
bound in triplicate for each condition and each lysate. Antibody plates were blocked with
charcoal-treated ovalbumin (1%w/v in PBS) for 1 h at RT. Tumor or cell line protein Triton
X-100 lysates were diluted with PBS (1:3) and 200 μl added with 80 μg of equivalent protein
for each sample tested. The plates were incubated on an orbital shaking platform overnight at
4°C and washed 5× with binding buffer and 1× with PBS, aspirated and air-dried. One well of
each antibody was eluted with SDS sample buffer (30 μl) and tested on SDS-PAGE and
immunobloted for sdAb recovery using anti-c-myc antibodies or silver stained. All wells
recovered the same qualitative amounts of primary sdAb being tested and no immuno-selected
proteins could be detected with silver stain. The duplicate remaining wells were treated in situ
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with sequencing grade porcine trypsin (Princeton Separations, Adelphi, NJ, USA) at 37°C for
3 h. The samples were transferred to a microfuge tube, dried by evaporation under vacuum
with centrifugation and resuspended in LC-MS/MS loading buffer [5% Acetic Acid, 5%
acetonitrile (ACN)]. The samples were then loaded individually onto a 100 μm C18 column
using a Famos Autosampler. Samples were then analyzed by on-line LC-MS/MS on a Finnigan
LTQ Iontrap mass spectrometer in a data-dependent MS/MS mode. The MS/MS spectra
generated from the 90 min gradient (5–80% ACN) were searched against NCBI-human
proteome database using the SEQUEST algorithm [45]. Stringent filtering criteria was used to
select for correct assignment with less than 1% false positive rates (Xcorr cutoff of 1.9 for 1
+, 2.2 for 2+, and 3.7 for 3+ peptides, delta Cn of 0.1, minimum of two unique peptide
identification for each protein). Only proteins selected with multiple or repeat peptides and in
duplicate for each sdAb tested were considered specific.
Stromal derived receptor-1/neuroplastin cDNA isolation and expression vector cloning
Human breast cancer cell lines, MDA-MB-231 and MCF-7 cells were obtained from ATCC
and cultured as recommended. Total RNA was isolated from cells using the Qiagen RNAeasy
kit. Total RNA (2 μg) was used in reverse transcription using Superscript II (Invitrogen) and
random hexamer primers as described above. Neuroplastin cDNA was amplified from 1/20th
of the RT reaction using coding region primers; ATG start codon: 5′-CAT GTC GGG TTC
GTC GCT GCC CAG-3′ and Termination: 5′-TTA ATT TGT GTT TCT CTG GCG CAA-3′.
Amplified sequences were cloned into pCR-T7/TOPO and sequenced to assure neuroplastin
clones. The full length cDNA was cloned into the pcDNA/V5/GW/D-TOPO expression vector
(Invitrogen) by amplifying the 5′-Kozak sequence and an oligonucleotide primer including the
last amino acid prior to the termination codon. 5′ primer sequence—5′-CAC CGA ATT CGC
CAT GTC GGG TTC GTC GCT GCC CAG-3′ and 3′ primer sequence—5′-ATT TGT GTT
TCT CTG GCG CAA-3′, human neuroplastin, beta isoform, NM_012428 (NPTN_036560.1).
Individual clones were sequenced to completion with three overlapping primers to assure no
mutations had occurred in the clones used.
Synthesis and analysis of human breast tumor tissue arrays
Human breast tumor tissue arrays were developed in house using a Beecher Instruments tissue
Arrayer (Beecher Instruments, Silver Spring, MD, USA). Forty de-identified breast tumor
formalin-fixed paraffin embedded tissue blocks were obtained from clinical pathology under
an approved IRB protocol. Two tumor arrays were established with duplicate cores from each
case consisting of 20 estrogen receptor alpha (ERα) negative and 20 ERα positive tumor
samples. Cores consisted of 1.0 mm cores from the most dense tumor areas as determined from
the H&E stained slide for each tumor block. A second breast tumor tissue array was obtained
from the NCI biological repository resource (NCINBR) which contained 280 individual cases
from normal ductal tissue to advanced metastatic lesions. Immunohistochemistry was
performed using anti-neuroplastin antibodies described previously [39]. Immunostaining was
developed with biotinylated secondary antibodies (Dako) and the Vector ABC kit (Vector
Laboratories), according to the manufacturers' instructions. Stained cores were assessed by
two independent observers using a scale of 0–4, representing zero to maximal staining
specifically in the tumor cells within each core.
Cell culture and transfection
MDA-MB-435S cells were obtained from ATCC (Bethesda, MD, USA) and cultured in
Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal bovine serum, 2
mM L-glutamine, 10 U/ml penicillin, and 10 μg/ml streptomycin under either normoxic (5%
CO2, 21% O2, 74% N2) or hypoxic conditions (5% CO2, 1.5% O2, 93.5% N2) in humidified
triple gas incubators at 37°C. Cells were stably transfected with a pcDNA 3.1 vector
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(Invitrogen) containing NPTN-beta isoform or eGFP cDNA using Lipofectamine™ Reagent
(Invitrogen) and selected with neomycin or geneticin as described previously [1].
Xenograft tumor model
MDA-MB-435S cells selected for NPTN or GFP expression were grown to 70–90%
confluence, trypsinized, washed with PBS twice, and resuspended in Hank's Balanced Salt
Solution to a final concentration of 1 × 107 cells/ml. Two hundred microliter (2 × 106cells) of
cell suspension was injected into the third axial mammary fat pad of 4 week old, female nude
mice using a 30 g needle affixed to a 1 cc tuberculin syringe. Tumor size was measured twice
per week and tumor volume calculated with the formula: Volume (mm3) = Length (mm) ×
Width (mm)2 × 0.52. Ten weeks after injection, the mice were euthanized, tumors removed,
weighed and split into thirds, with one-third frozen in optimal cutting temperature
cryosectioning media (OCT), one-third flash frozen in liquid nitrogen and a third formalin
fixed and paraffin embedded for histological analysis.
Immunohistochemistry and histological quantification
Tumor cryo-sections were obtained (7 mm) and immuno-stained for vessels using the anti-
human CD31 monoclonal antibody (Santa Cruz Biotech, Santa Cruz, CA, USA) at a 1:100
dilution. Positive staining was detected as described above. Tumor microvascular density was
obtained by imaging three high power fields in areas of viable tumor and capturing digital color
images. A pixel-by-pixel quantification of DAB staining was performed using Image Pro Plus.
Pixels were normalized to the average pixel per vessel as defined by the value obtained from
ten independent microvessels in cross section/10 to estimate total vessels per area.
Protein extraction and VEGF ELISA
MDA-MB-435 cells or tumors from the xenograft experiment were lysed in Triton X-100 lysis
buffer (1% Triton X-100, 50 mM Hepes, pH 7.5, 10 mM sodium pyrophosphate, 150 mM
NaCl, 100 mM NaF, 0.2 mM sodium orthovanadate, 1 mM EGTA, pH 7.5, 1.5 mM MgCl2,
10% glycerol, and fresh protease inhibitor cocktail (10 μl/ml) (Sigma)). Protein concentrations
were determined using Biorad DC protein assay (BioRad Inc.) according to the manufacturer's
instructions. A human VEGF sandwich ELISA was performed as described previously [37].
RNA Isolation and qRT-PCR
Cores (2 mm) were removed from human breast tumor samples and RNA was isolated with
the RNeasy kit (Qiagen) according to the manufacturer's protocol. Reverse transcription
reactions and quantitative PCR was performed as previously described [29]. NPTN-beta
(NM_012428) expression was normalized to the ribosomal transcript RPL0 (NM_532753).
Primers used for qRT-PCR were: NPTN-beta (NM_012428) forward 5′-TGTGCTGAGAAT
AACCCGGCT-3′, NPTN-beta reverse 5′-TTGGCTTCTG AAGGACGCTTA-3′, RPL0
(NM_053275.3) forward 5′-TCCTCGTGGAAGTGACATCGT-3′, RPL0 reverse 5′-
CTGTCTTCCCTGGGCATC-3′.
Statistical analysis
Data from individual experiments were represented as mean ± standard error unless otherwise
stated. Statistical comparison of groups was performed using 2-tailed Student's t test, ANOVA,
or Chi-square with appropriate tests for equal variances. Statistical significance was defined
and indicated as P ≤ 0.05 (*) or P ≤ 0.01 (**).
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Results
B cell activation and proliferation zones can be identified in tumor-draining lymph nodes
from breast cancer patients by multiplex immunostaining
Our first objective was to establish if B cell activation and proliferation, both hallmarks of
antigen-driven immune responses, can be detected in tumor-draining lymph nodes from breast
cancer patients. To achieve this, 32 sentinel tumor-draining lymph nodes were stained for three
markers: CD20, a B cell-specific cell surface molecule; CD23, an indicator of B cell activation,
which is not expressed on plasma cells [33]; and Ki67, a proliferation marker [36]. As shown
in Fig. 1, multiple CD20-positive zones were found in each lymph node (average 42.5 zones
per node), but only 27% of these were positive for CD23. Interestingly, clusters of Ki67+ cells
within the CD20+CD23+ zones were rare (1.13 clusters per lymph node on average), indicating
that only a small fraction of B cell clusters were proliferating at the time of surgical resection.
These results indicate that zones of B cell activation and proliferation can be identified in frozen
lymph node samples and that they account for just a small proportion of the total area occupied
by B cells in each sentinel lymph node. These zones may represent active germinal centers
where antigen-driven B cell proliferation was taking place.
Clonal expansion and somatic hypermutation events can be identified in proliferative B cell
zones
Next, we wanted to determine if signs of antigen-driven immune responses could be detected
in activated B cell zones that were defined by immunohistochemistry with activation and
proliferation markers. Our approach was to core either proliferative (Ki67+) CD20+CD23+ or
non-proliferative (Ki67−) zones from the same lymph node and isolate total RNA for the
generation of VH cDNA sequence libraries. Forty-six complete open reading frame sequences
were obtained from the Ki67+ B cell zone and 50 from its Ki67− counterpart. These sequences
were analyzed to determine V, D and J gene segment usage and to establish if mutations in the
complementary determining regions (CDRs) were caused by antigen pressure. Four groups of
sequences that shared the same VDJ rearrangement were found in the Ki67+ library, Table 1.
These groups included three pairs and a group of four for a total of ten sequences, which
represented 21.7% of the library. Conversely, the Ki67− library had a single pair of sequences
with matching VDJ segments, representing only 4% of the sequences recovered, Table 1.
Significant clustering of replacement mutations in CDR1&2 was found in 52.5% of the
sequences from the Ki67+ library, while 22% of the sequences showed this characteristic in
the Ki67− pool, Table 1. When considering only sequences that where part of clonal groups,
three of the four groups in the Ki67+ library had significant replacement mutations in their
CDRs as determined by the algorithm of Lossos et al. [26]. None of the sequences in the
Ki67− group had significant mutational events. In total, eight out of ten clonal sequences (80%)
had signs of somatic hypermutation (SH). As shown in Fig. 2, alignment of the CDR sequences
from the groups sharing VDJ rearrangements show that several mutations were shared,
although most clones had different sequences. Two pairs of sequences (clones D11/B10 and
C8/E12) had identical CDRs, although their sequences were not identical overall. This
distribution strongly suggests that the sequences that shared the same VDJ rearrangement
originated from one clone and that their mutations were caused by antigen pressure. In
summary, clonal groups with mutations indicative of antigen selection were found only in
clones sequenced from the proliferative B cell zone library. These results indicate that both CE
and SH were present in the VH sequences obtained from the CD20+CD23+Ki-67+ zone and,
consequently, that antigen-driven immune responses could be identified in tumor-draining
lymph nodes based upon B-cell activation and proliferation markers.
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Single domain antibodies extracted from tumor-draining lymph nodes can be used to identify
new tumor antigens
Our analysis of several tumor-draining lymph node sections and two VH sequence libraries
obtained from one of them showed that antigen driven humoral immune responses can be
detected in these tissues. However, the origin and identity of the antigens could not be
determined with this type of analysis. Our possession of VH sequences with evidence of
antigen-driven mutations prompted us to devise a method to screen for, and to identify potential
tumor antigens. There is ample evidence that VH domains alone (termed sdAbs) retain antigen-
binding properties and can be used to screen protein samples [17,18,46]. Therefore, we
developed an assay to trap tumor antigens with recombinant sdAbs synthesized with the VH
sequences retrieved from the tumor-draining lymph node. Since the accumulation of
replacement mutations in CDRs indicates antigen pressure, we selected a sequence from the
Ki67+ library with high CDR1&2 mutational events (clone A3; P = 0.005). As a control, a
sequence from the Ki67− library with the same V and J segments, but with no significant
clustering of replacement mutations in the CDRs was chosen (clone H1, P = 0.746). As shown
in Fig. 3a, these sequences differ mainly by their variation in CDR domains.
The sequences were cloned into a bacterial expression vector which provides a C-terminal
myc-epitope tag and a 6× His purification tag. Both proteins were synthesized in bacteria and
the purified recombinant sdAb proteins dialyzed to promote refolding. The protein production
and purification was followed by anti-myc immunoblots to normalize the amounts of purified
sdAb proteins obtained (data not shown). The purified sdAbs were allowed to bind to nickel-
coated plates and used to select proteins from tumor extracts obtained from the same patient
as the lymph node VH library. Proteins trapped by sdAbs were subjected to in-solution direct
trypsin protease digestion and peptides released were analyzed by LC-MS/MS. One peptide
(IVTSEEVIIR) was identified multiple times in the tumor protein selection and peptide
analysis by LC-MS/MS with the A3 sdAb but not in the control H1 protein trap. A protein
database search revealed that this peptide matched with a member of the Ig superfamily of
proteins, neuroplastin (NPTN), also called Stromal Derived Receptor-1 (SDR-1), Fig. 3b. The
H1 sdAb did not trap and identify proteins with high confidence by LC-MS/MS from the same
extract performed in the same plate and at the same time.
NPTN is a transmembrane glycoprotein originally described as a component of synaptic
membranes in rat brain [39]. Two alternatively spliced isoforms exist: NPTN-65, a brain-
specific isoform with three extracellular Ig-like domains and NPTN-55, a widely expressed
isoform that has only two Ig-like domains [24,25]. To confirm the specificity of the A3 sdAb,
we tested it as a detection reagent in immunoblots and compared it to the signal obtained with
an antibody raised against the NPTN-65 protein. Five breast tumor protein extracts were
assayed, including the sample in which the NPTN protein was identified. The anti-NPTN
antibody revealed the presence of a 55 kDa isoform in all tumors tested and an alternative 45
kDa band that varied in intensity among samples, three of them having a stronger signal, Fig.
3c. Probing with the A3 sdAb resulted in the presence of the 45 kDa bands, closely resembling
the pattern found with the anti-NPTN antibody, albeit with a weaker signal. The A3 sdAb also
detected bands at 55 kDa. These results suggest that A3 is a sdAb specific for NPTN and
confirms the presence of NPTN in the tumor sample used for the antigen-trapping assay.
Neuroplastin is expressed in a subset of human breast cancers
To better understand the expression of NPTN within a population of breast cancers, we
evaluated a human breast tumor tissue array containing cores of normal breast tissue and
invasive breast carcinoma using immunohistochemistry using a polyclonal anti-NPTN
antibody that had been previously used to characterize NPTN expression in rodent and human
tissues [5,39]. A subset of invasive carcinoma samples had significant positive staining in
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tumor cells but not in the adjacent stroma, while normal breast tissue was negative, Fig. 4a–d.
To quantify the data, the extent of NPTN-immunostaining was scored from 0 to 4 by two
independent observers. While only one out of 40 (2.5%) normal breast tissue samples had a
score of 3 or higher, 38 out of 179 (21.2%) invasive carcinoma specimens showed a positive
staining for NPTN using the same threshold. Interestingly, when grouping the cases according
to the presence of lymph node or distant metastasis, a larger percentage of NPTN-positive
tumors was found in the group that had distant metastasis, Fig. 4e, indicating that NPTN
expression may promote tumor invasion and/or metastatic potential.
Over-expression of NPTN in MDA-MB-435 breast carcinoma cells confers a growth
advantage in vivo
Like other members of the Ig superfamily, NPTN participates in cell adhesion phenomena
[10,39] and could have profound effects on tumor biology. To test this hypothesis, we
transfected the breast cancer-derived cell line MDA-MB-435 with a vector expressing the
NPTN beta protein tagged with the V5 peptide or EGFP as a control. Cell pools were selected
with neomycin resistance using geneticin-sulfate and evaluated for protein expression by
immunoblot, Fig. 5a. Expression of a ∼49 kDa protein was detected by anti-V5 Western blot
in two MDA-MB-435 pools (1&2) stably expressing NPTN. MDA-MB-435 cells transfected
with GFP were used as controls for background staining. To assess whether the NPTN isoform
was highly glycosylated as reported in the literature, extracts were exposed to both N- and O-
linked glycosidases and evaluated by immunoblot. The main 49 kDa isoform was observed to
be reduced to an apparent molecular weight of 37 kDa after glycosidase treatment. Some of
the glycosylated form was still present indicating that de-glycosidation was not quite complete.
Immunoblot for β-actin showed equal loading of extracts in each lane.
To evaluate whether the expression of NPTN in the MDA-MB-435 cell line affected optimal
growth in vitro, we plated cells stably expressing EGFP (GFP) and the highest NPTN
expressing line, pool 1, and assessed cell viability over time using an MTT assay, Fig. 5b.
There were no significant differences in overnight cell seeding (time 0), or proliferation rates
over 48–72 h. The cell pools even demonstrated identical growth suppression based upon
confluency and media nutrient consumption at 72 h. Analysis of a 1:1 mixture of the GFP cells
with the NPTN pool 1 (NPTN:GFP) also showed nearly identical seeding and growth curves
over 72 h. NPTN-expressing MDA-MB-435 cells were also assayed for survival during glucose
deprivation, anchorage independent growth and invasion through Matrigel matrix barrier, and
showed no difference from the GFP control cells in each of these assays (data not shown).
Evaluation of the breast tumor cells in culture suggest that the NPTN expression does not affect
growth pathways in the MDA-MB-435 cell line either directly or through secreted mediators.
However, it has been demonstrated that Ig proteins with homology to NPTN, such as Basigin/
CD147/EMMPRIN have unique effects on stromal cells and within the tumor
microenvironment. For example, Basigin/CD147/EMMPRIN demonstrated the ability to be
shed from the cell surface and act upon stromal cells to induce migration and VEGF angiogenic
gene expression [41,44,47]. Thus, to assess whether NPTN over-expression might promote
tumor growth or metastasis, cells were implanted into athymic nude mice in the mammary
orthotopic site to test tumor growth over time, Fig. 6a. Ten weeks after injection into the
mammary fat pad, MDA-MB-435 cells over expressing the NPTN protein showed a
significantly improved tumor growth with larger tumor volumes (614.8 ± 132.6 vs. 247.0 ±
29.4 mm3; P = 0.032); as well as tumor weights at harvest (366.7 ± 64.0 vs. 138.3 ± 17.7 mg;
P = 0.024) compared to the GFP expressing control cells. Interestingly, vascular staining with
anti-CD31, revealed that NPTN-overexpressing tumors had enhanced blood vessel formation
and a highly integrated vascular network, Fig. 6b. To test the hypothesis that the NPTN-
overexpressing cells could produce this effect through increased vascular endothelial growth
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factor (VEGF) production, the levels of VEGF were assayed in tumor lysates and in cell culture
supernatants of the transfected cells. Tumors derived from the NPTN-transfected cells showed
a fivefold increase in VEGF content in vivo, Fig. 6c. Likewise, when the MDA-MB-435 cells
were challenged with hypoxia in culture, the NPTN-expressing cells demonstrated increased
VEGF production when compared to GFP-expressing controls, Fig. 6d. Taken together, these
data support a model for NPTN-enhanced tumor growth through an angiogenic mechanism
mediated by increased production of VEGF. This function is likely related to some contribution
of NPTN to tumor cells in response to microenvironmental hypoxia, a mechanism that will
have to be investigated with more detailed experiments.
Neuroplastin beta correlates with angiogenic phenotype in primary human breast cancer
Immunological detection of NPTN isoforms and the complexity of post-translational
modification by glycosylation cannot ascertain the NPTN isoform(s) that are prevalent in
human breast cancer. To address which NPTN isoform is expressed in human breast cancers
we performed qRT-PCR for NPTN-alpha and NPTN-beta on mRNA isolation from estrogen
receptor alpha (ERα) positive, MCF-7 breast carcinoma cells and the ERα negative MDA-
MB-231 cells. The data indicated that the NPTN-beta isoform was expressed and was the
dominant isoform in MDA-MB-231 cells and very little amplification of NPTN-alpha or beta
was observed in MCF-7 cells (data not shown).
In an effort to determine if NPTN-beta expression was related to selective human breast cancer
phenotypes, we analyzed its expression in 16 primary breast cancer cases. To avoid excess
contamination by non-tumor cell types, tumor samples were obtained by sampling only tumor
dense areas from a frozen block using a 2 mm biopsy punch. NPTN-beta mRNA levels, as
determined by qRT-PCR, were compared to patient age, tumor size, hormone receptor and
Her-2/neu status, as well as angiogenesis, Table 2. Interestingly, the top quartile for NPTN-
beta expression was twofold higher than the average of the total and ten-fold higher than the
bottom quartile. There appear to be no selectivity or correlation with patient age or tumor size;
in fact the tumor sizes were generally smaller in the upper quartile of NPTN-beta expression.
Surprisingly, all four samples in the upper quartile were triple negative for ERα, PR, and Her-2/
neu. Despite slightly smaller tumor size, the level of angiogenesis in the upper quartile was
two-fold higher than the lower quartile and was statistically significant. The microvascular
density (MVD) in tumors with high NPTN-beta expression was also higher than the average
of the total; however, this did not reach significance due to high variance in the individual
tumors. Analysis of whether NPTN-beta expression correlated with tumor angiogenesis was
found to be highly significant using Pearson's correlation statistic (R2 = 0.7566, P = 0.0243).
Thus, even in a small pilot study, the expression of NPTN-beta may have a significant impact
upon tumor angiogenesis and subsequently metastatic potential.
Discussion
In the present study, we describe a novel scheme for the identification of TAAs using human
tissues. Because it is likely that antigen-driven B cell proliferation in tumor-draining lymph
nodes can be activated by TAAs, our first endeavor was to identify areas within the lymph
node where such proliferation events were taking place. Immunohistological evaluation of B
cell proliferation in tumor-draining lymph nodes using Ki67 as a marker resulted in the
identification of very few proliferative zones in each sample (approximately one or two in each
lymph node). In germinal centers, Ki67 is expressed in the centroblast-rich dark zone and is
lost during B cell differentiation [3,23,31]. Thus, when Ki67 signal was overlayed onto the
anti-CD20 and -CD23 signals, the triple stain pattern adequately identifies clusters of B cell
activation and proliferation, a good indication that these corresponded to germinal centers
where an immune response was developing at the time of resection.
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To examine this possibility further, Ig VH domain cDNA libraries were generated from either
the CD20+CD23+Ki67+ and CD20+CD23+Ki67− zones from one lymph node. Our analysis
demonstrated that CE is present to a much larger extent in the Ki67+proliferative zone when
compared to Ki67− areas. Furthermore, evaluation of mutations from the closest matching
germline genes using a stringent method previously described [26] shows that the distribution
and characteristics of SH was present in a significantly higher percentage of sequences from
the proliferative zone VH library. These data point toward the possibility of identifying zones
with antigen-driven humoral immune responses in frozen tumor-draining lymph node samples
by combining immunohistochemistry and Ig VH sequence analysis. Despite a unique and
potentially useful approach to identify active germinal centers within a tumor-draining lymph
node, these analyses; however, cannot assess whether these events are evoked by the tumor or
some basal cycling events within lymph nodes, something that will have to be evaluated in a
larger population study.
A significant application of this approach was the ability to utilize the CE and SH VH gene
sequences to screen for, and identify potential novel tumor antigens. The discovery of naturally
occurring antibodies devoid of light chains in camelids [15] has led to the characterization of
sdAbs as highly versatile molecules with potential as diagnostic and therapeutic applications
[18]. These sdABs retain antigen-binding capacity and can be synthesized as a stable molecule,
and are significantly smaller than full-length antibodies or even scFv recombinant proteins.
These characteristics make them uniquely suitable for antigen discovery. A previous study by
Zhang et al. [46] used a pentavalent sdAb to identify a candidate TAA from a non-small cell
lung carcinoma cell line using proteomic analysis, proving that these reagents can select
specific proteins from a complex sample. In this study, we selected a VH sequence that showed
a significant SH pattern to synthesize a recombinant sdAb, which could be bound to a solid
matrix and served to trap a specific protein from tumor lysates, NPTN a potential breast cancer
antigen. Since the VH gene was derived from the same lymph node sample as the patient tumor
and, the non-CE/SH control sdAb did not select NPTN, we speculate that an NPTN-specific
immune response was detected in the lymph node and served to produce this specific VH
sequence. Further evidence for this may have been possible if patient serum was available,
however, a matched serum was not available from this patient. These results do however, raise
the exciting possibility that this procedure for the discovery of TAAs using antibody sequences
selected by immune activation in tumor-draining lymph nodes is entirely possible and in fact
may be very efficient and effective.
The identification of NPTN as a potential breast cancer antigen is not surprising since multiple
antigens have been identified that are surface molecules with high glycosylation content [4,
11,16,28,32]. NPTN is a surface molecule containing multiple immunoglobulin-like
extracellular domains which share homology with those of Basigin/CD147/EMMPRIN gene.
The 65 kDa neuronal-specific isoform has been shown to participate in long-term potentiation
in neural synapses through homophilic adhesion that triggers p38MAPK activation [10,39].
Several investigations have indicated that the Basigin/CD147/EMMPRIN family of proteins
promote monocarboxylate transporter proteins which are critical for lactate and pyruvate
shuttling into and out of cells during metabolic stress [20]. In this study, the overexpression of
NPTN beta in a breast cancer cell line significantly enhanced tumor growth and angiogenesis
in vivo. The enhanced tumorigenesis correlated with a higher VEGF content in the tumors as
well as a more robust production under hypoxic conditions in vitro. Interestingly, CD147 is a
molecule which can be highly expressed in tumors and has also been shown to stimulate VEGF
production by both tumor and stromal cells when expressed in a breast cancer cell line [40].
In an interesting preliminary screen, it was found that NPTN-beta expression also correlated
with primary human breast tumor angiogenesis. Thus, our results implicate NPTN as another
member of the Ig superfamily that, when aberrantly expressed by transformed cells, can confer
a growth advantage to malignant tumors. The specific mechanism of this response is thus far
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unclear and may involve tumor microenvironmental signals. Here we determined that
environmental hypoxia, when combined with NPTN overexpression, further promotes the
expression of VEGF above the level observed in control cells. Thus, NPTN expression may
increase the sensitivity or ability to synthesize additional VEGF in tumor cells. A mechanism
for this process may be complicated and implications for increased HIF-1 activity, post-
transcriptional mRNA stability and even potentiation of translation and vesicular trafficking
are all possible and need to be investigated further. The increased VEGF expression may be
one explanation of the correlation of NPTN expression with highly invasive and the distally
metastatic breast cancers, suggesting that NPTN may promote survival in the circulation and/
or invasion and survival at a distal site. Finally, NPTN expression appears to represent multiple
glycoforms in human breast cancer suggesting that it may be shed from the cell surface by
proteases or there may be alternative patterns of glycosylation in some tumors. Alternative or
aberrant glycosylation could be a mechanism that would promote the antigenicity of this
protein, especially if shed from the tumor microenvironment at high levels.
The identification and evaluation of a large number of potential antigens, particularly
alternative forms of proteins normally expressed, may be a useful approach to define novel
cancer biomarkers for primary and metastatic cancers. Although this study effectively used
patient derived VH domain antibody to define a breast cancer antigen, it remains to be seen
whether this is a robust method applicable to breast and other cancers. The use of a patient-
activated humoral response to provide the tools for this approach has been demonstrated here
and should be applicable to many other human cancers.
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Fig. 1.
Immunohistological analysis of B cell zones in tumor-draining lymph nodes from breast cancer
patients. a Immunohistochemistry staining for CD20, CD23 and Ki67 in serial sections of a
tumor-draining lymph node (bar = 1,000 μm). b Merged image of the three stains in the zone
highlighted in a. Masks of different colors were applied to each marker: CD20 yellow, CD23
blue, and Ki67 pink (bar = 1,000 μm). c Number of zones positive for CD20, CD20 and CD23
or a combination of the three markers in each lymph node (average and standard deviations
are shown, n = 32)
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Fig. 2.
Alignment of amino acid sequences of the CDRs of VH clones that shared VDJ rearrangements.
The VH, DH and JH gene segments used by each clonal group from a Ki67+ and Ki67− libraries
are indicated. Amino acid sequences are provided for each clone and aligned with similar
VH, DH, and JH clones. Dashes indicate same amino acid sequence and asterisks (*) above
each amino acid indicates difference from germline sequence (not shown). Locations of silent
mutations are indicated by open circles above their respective amino acids. CDR3 sequences
could not be compared to germline through direct database matching thus differences from
germline are not reported for CDR3. The p value for clustering of replacement mutations in
CDR1&2 (pCDR) according to the method described by Lossos et al. [19] are provided for
each clone, P ≤ 0.05 is considered significant
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Fig. 3.
Identification of NPTN in tumor protein extracts. a Alignment of amino acid sequences of A3
and H1 sdAbs. Dashes indicate same amino acid between A3 and H1 clones. Replacement
mutations in FRs 1, 2 and 3 and CDRs 1 and 2 are indicated by an asterisk (*), CDR3 was not
directly compared to germline sequences (germline sequence not shown). Gray boxes indicate
CDRs 1–3. b Amino acid sequence of NPTN beta. The peptide identified by LC-MS/MS is
boxed. c Immunoblot of 5 primary breast tumor samples using anti-NPTN (NP) (top panel) or
A3 sdAb (tagged with c-myc) and detected with anti-c-myc antibody (bottom panel)
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Fig. 4.
Neuroplastin is expressed in a subset of breast tumors. A tissue array containing normal breast
and breast cancer tissue cores was stained by immunohistochemistry with an anti-NPTN
antibody. Representative cases are shown: a Normal breast, b Invasive ductal breast carcinoma,
node negative. c Invasive ductal breast carcinoma, node positive. d Invasive ductal breast
carcinoma, distant metastasis (bar = 100 μm). e Percentage of cases from each group that had
a score of 3 or higher for NPTN staining; N0 node negative, N ≥ 1 node positive, M1 distant
metastasis
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Fig. 5.
NPTN expression in MDA-MB-435 cells does not affect in vitro cell growth. a The stable
expression of NPTN in MDA-MB-435 cells by immunoblot. Top panel Detection of V5 epitope
tag in extracts from parental MDA-MB-435 (435) cells, cells expressing EGFP (MDA-
MB-435-GFP) (GFP), and two lines expressing NPTN-V5 (NP-1, NP-2), middle panel
Detection of V5-epitope after treatment of extracts with N- and O-glycosidases. Bottom
panel Control for extract loading with β-actin immunoblot. b MTT viability assay of cells
plated in triplicate after overnight seeding (time 0), 48 and 72 h later. MDA-MB-435-GFP
(GFP), MDA-MB-435-NPTN (NP) and a 1:1 ratio of both (NP:GFP) cells were analyzed. No
statistical difference was observed at any time point
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Fig. 6.
NPTN expression in MDA-MB-435 cells stimulates tumor growth and angiogenesis in vivo.
a Control MDA-MB-435 or NPTN-transfected (NP) cells were injected into the mammary fat
pad of athymic nude mice and tumors were measured twice a week. Average tumor volumes
(ave. ± SEM) for NPTN-transfected (filled square) and control (open circle) tumors are shown
(n = 7). b Vascular immunostaining (CD31) in MDA-MB-435-GFP tumors (Control) or
NPTN-overexpressing (NP) tumors. Two representative cases for each group are shown (bar
= 100 μm). c VEGF protein expression in NPTN-overexpressing and control tumor lysates
normalized to the total amount of protein in each sample (n = 7). d Hypoxia induced VEGF
secretion into media by MDA-MB-435 cells (control) or with overexpression of NPTN (NP)
over 24 h (n = 3) (*P ≤ 0.05)
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